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Cancer arises through the accumulation of both genetic and epigenetic alter-
ations. Although the causal role of genetic mutations on cancer development has
been established in vivo, similar evidence for epigenetic alterations is limited.
Moreover, mutual interactions between genetic mutations and epigenetic alter-
ations remain unclear. Cellular reprogramming technology can be used to actively
modify the epigenome without affecting the underlying genomic sequences.
Here we introduce recent studies that have utilized this property for cancer
research. We propose that just as it has potential for regenerative medicine and
disease modeling, cell reprogramming could also be a powerful tool for dissect-
ing the role of the cancer epigenome in the development and maintenance of
cancer cells.
C ancer arises through the accumulation of multiple geneticalterations, suggesting it is a genetic disease.(1) However,
many studies have revealed that the initiation and promotion
of cancer development are accompanied by various epigenetic
alterations, which are often characterized by epigenetic modifi-
cations that differ from those in normal cells.(2–4) For instance,
overall DNA methylation levels are reduced in most cancer
cells,(5) while site-specific DNA hypermethyaltion at gene pro-
moters(6) is one of the most extensively analyzed alterations in
cancer cells.(7) A role of an altered epigenome in cancer devel-
opment has been demonstrated previously. For example,
reduced DNA methylation increases chromosomal instabil-
ity,(8,9) leading to increased tumor frequency in vivo.(10,11) In
contrast, DNA hypermethylation is mainly associated with the
silencing of tumor suppressor genes, such as p16ink4A,(12,13)
VHL,(14) BRCA1(15) and LKB1.(16) Indeed, a suppressive effect
through the forced reduction of DNA methylation on cancer
development has been shown in several cancer models.(17–23)
However, the mechanisms driving these epigenetic changes
during carcinogenesis are poorly understood.
Recent genome-wide sequencing studies have revealed that
epigenetic modifier genes are often mutated in many types of
cancers.(24–26) Both activating(27) and inactivating(28,29) muta-
tions of Ezh2, which encodes a catalytic subunit of polycomb
repressive complex 2 (PRC2), have been identified in certain
types of cancers. Tet2, which is associated with 5hmC produc-
tion and DNA demethylation, is also mutated in myeloid
malignancies and other hematological disorders.(30) These find-
ings strongly suggest that genetic abnormalities are the primary
cause of the altered epigenome in cancer cells.
It should also be noted that epigenetic modifications are
tightly coupled with transcriptional regulations. Generally,
oncogenic signals affect the transcriptional regulation of down-
stream target genes, thereby resulting in altered transcriptional
networks. Given that oncogenic signals are often activated by
genetic mutations, altered epigenetic patterns could be a sec-
ondary effect of the transcriptional changes caused by the
genetic alterations.
In addition, epigenetics regulates the adaptation of transcrip-
tional networks to the extracellular environment, such as nutri-
tion levels, oxygen concentration and inflammation. Thus, for
some cancers, it has been proposed that such environmental
factors could induce epigenetic alterations. In particular,
inflammation is considered a key environmental factor for both
cancer development and epigenetic modifications in cancer
cells. Dextran sodium sulfate (DSS), an inflammation inducer
that is also a potent tumor promoter in the colon, causes
abnormal hypermethylation at DNA methylation valleys in
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murine colonic crypts.(31) Similarly, Helicobacter pylori infec-
tion, which is closely associated with gastric cancer develop-
ment in both humans and rodents, causes abnormal DNA
methylation in normal gastric mucosa.(32,33) Notably, a subset
of epigenetic alterations caused by such inflammation are con-
sistent with those in cancer cells, suggesting that environmen-
tal factors may contribute to cancer development by inducing
epigenetic alterations.(34) Considering that these environmental
factors are independent of any genetic abnormalities in cancer
cells, inflammation-dependent epigenetic alterations could be
an independent cancer driver of genetic abnormalities.
All together, both genetic mutations and environmental fac-
tors can induce epigenetic alterations in cancer cells. Given
that the correction of genetic mutations is not a feasible cancer
therapy, epigenetic alterations caused by environmental factors
may make better targets. However, it remains unclear to what
extent environmental factors inducing epigenetic modifications
play in cancer development (Fig. 1).
The study of this relationship may benefit tremendously from
cell reprogramming methods, of which there are three. In the
first method, nuclear transplantation, the nucleus of a somatic
cell is transferred into an enucleated oocyte.(35) In the second
method, cell fusion, a somatic cell is fused with an embryonic
stem cell (ESC).(36) Finally, the third method, induced pluripo-
tent stem cells (iPSC), describes somatic cells that have been
converted to a pluripotent state by the transient induction of
reprogramming factors (Oct3/4, Sox2, Klf4 and cMyc).(37,38)
Along with pluripotency, iPSC exhibit unlimited growth capac-
ity and, therefore, can be a promising cell source for regenera-
tive medicine, disease modeling and drug discovery.(39–43) It has
been shown that dynamic changes of the epigenome occur dur-
ing the reprogramming, whereas changes in the underlying geno-
mic sequences are not required.(44,45) Therefore, reprogramming
technology could be a useful strategy for dissecting the role of
genetic mutations and epigenetic alterations in cancer cells.
Cancer Cell Reprogramming
To study the role of epigenetic alterations in cancer develop-
ment, one promising strategy would be to investigate the phe-
notypic consequence of a manipulation of the cancer
epigenome. Because epigenetic regulations play a pivotal role
in cell fate determination and their maintenance, the cell fate
control by reprogramming technology should be accompanied
by dynamic changes of the epigenome. Hochedlinger et al. (46)
report the reprogramming of the cancer nucleus by nuclear
transplantation. Notably, the oocytes that received the cancer
nuclei were subsequently able to form a blastocyst-like struc-
ture. The authors further succeeded to establish nuclear trans-
ferred ESC (ntESC) with the melanoma nucleus of
tetracycline-inducible HRAS transgenic mice,(46) demonstrating
that the cancer genome is reprogrammable into the pluripotent
stem cell state. However, ntESC could not be generated when
using nuclei from other types of cancer cells, such as leuke-
mia, lymphoma and breast cancer cells. This inability suggests
that cancer cells exhibit refractoriness to nuclear reprogram-
ming. Notably, there are several reports that have succeeded to
establish iPSC from cancer cells. These studies have revealed
interesting insights of the cancer epigenome with regards to
the lineage specificity of oncogenes,(47,48) recapitulation of
cancer progression(49) and cancer cell heterogeneity
(Fig. 2).(50)
Lineage specification of oncogenes. Specific cancers are often
associated with mutations at specific genes.(51) For example,
HER2 amplification is preferentially observed in breast can-
cers,(52) and EGFR mutation is frequently detectable in lung
cancers.(53,54) Patients with familiar adenomatous polyposis
(FAP) show a mutation in the APC gene and develop cancers
predominantly in the colon, although cells throughout the
patient body will harbor mutations in this gene.(55) These
observations suggest that the genetic mutations require the
specific cell type to exert cancer properties.
Carette et al.(47) established iPSC from human chronic mye-
loid leukemia (CML) cells that harbor the BCR-ABL fusion
gene. CML-derived iPSC lost sensitivity to tyrosine kinase inhi-
bitors (TKI) that targeted BCR-ABL despite expression of the
BCR-ABL gene. Intriguingly, the TKI sensitivity was recovered
when CML-iPSC were differentiated into hematopoietic cell lin-
eage cells.(47) Given that the iPSC and hematopoietic lineage
cells share the same genetic context, these results indicate that
TKI sensitivity depended on the differentiation status of cells
with distinct epigenetic regulation.
Similarly, Stricker et al.(48) established glioblastoma (GBM)-
derived iPSC from GBM-derived neural stem cells. Re-differ-
entiation of the GBM-iPSC into neural progenitors resulted in
highly malignant cells when injected into immunocompro-
mised mice. However, GBM-iPSC did not exhibit the malig-
nant phenotype when differentiated into non-neural lineage
cells. These results too suggest that genetic mutations render
the cells malignant only when a particular cell type with the
unique epigenetic state is met.(48)
Recapitulation of human cancer progression. In vivo cancer
models are often used to study the molecular mechanisms for
the cancer initiation and progression, but species differences
between humans and rodents have compromised the develop-
ment of effective cancer therapies and the recapitulation of
oncogenesis in human cancer cells. For this reason, iPSC may
make a better model.
Kim et al.(49) succeeded in establishing iPSC from human
pancreatic ductal adenocarcinomas (PDAC) that can be main-
Fig. 1. Crosstalk between genomic and epigenetic
abnormalities during cancer development. Cancer
arises from a somatic cell accumulating genetic and
epigenetic abnormalities. During its progression,
external factors cause additional genetic and
epigenetic changes in the cell. The genetic
abnormalities can regulate the epigenetics via
alterations in transcriptional networks. In contrast,
the epigenetic abnormalities can regulate genomic
integrity through chromosomal instabilities.
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tained under the low level expression of exogenous 4Fs. Upon
the induction of differentiation, the PDAC-iPSC differentiated
into three germ cell layers and formed teratomas, reflecting
their pluripotency. Interestingly, these PDAC-iPSC-derived ter-
atomas contributed to endodermal ductal structures, which
exhibited a similar histology to pancreatic intraepithelial neo-
plasia (PanIN), a premalignant lesion of PDAC. The authors
proposed that PDAC-iPSC can recapitulate the early stage of
pancreatic cancer development upon their differentiation, and
that this disease model could be useful for studying the pro-
gression of human pancreatic cancer cells. Furthermore, it was
shown that the HNF4a is involved in the pancreatic cancer
progression and invasion, and, thus, could be a therapeutic tar-
get. Taken together, multipotent cancer cells established by
reprogramming technology have provided a useful platform for
studying human cancer genome–epigenome interactions and
discovering key molecules in cancer progression.
Hierarchy of heterogeneous cancer cells. Cancer cells are
notoriously heterogeneous, a property that can be attributed to
their genetic and epigenetic variations.(56) It has been sug-
gested that heterogeneity could be a driving force in cancer
progression and is a fundamental basis of the cancer stem cells
(CSC) concept.(57) In this concept, a CSC population resides
atop the hierarchy and has the potential to give rise to hetero-
geneous cancer cells and reconstitute tumor mass. However,
the hierarchy of heterogeneous cancer cells is not fully under-
stood. Suva et al.(50) report that differentiated glioma cells can
be converted into CSC-like populations by the forced expres-
sion of a specific set of transcription factors (POU3F2, SOX2,
SALL2 and OLIG2), which are highly expressed in stem-like
glioma cells. The forced expression of these factors in non-
CSC-like glioma cells reorganized the transcription network
and epigenetic landscape into a CSC-like state. Furthermore,
the authors also identified LSD1 and RCOR1, which mediate
the demethylation of H3K4, as an epigenetic switch for the
conversion of non-CSC-like glioma cells into CSC-like glioma
cells. Consistently, they showed that an LSD1 inhibitor
induced the ablation of stem-like glioma cells and that LSD1
knockdown have prolonged survival time and reduced tumori-
genic potential in vivo. These findings support the concept that
control of CSC-like glioma cells and differentiated glioma
cells is governed by epigenetic regulation. Similarly, a recent
study demonstrated that biological interconversion between
glioma stem-like cells and differentiated glioma cells is rever-
sible and functionally plastic.(58) Notably, this interconversion
is accompanied by gain or loss of PRC2-mediated H3K27me3
Fig. 2. Application of cell reprogramming to cancer
biology. (a) Cell reprogramming can alter the
epigenome of a cancer without affecting genetic
abnormalities. (b) Cell reprogramming as a tool for
dissecting the unique properties of cancer cells.
(1) Reprogramming of chronic myeloid leukemia
(CML) cells showed epigenetic background-specific
oncogenic addiction. (2) Re-differentiation of cancer
cell-derived iPSC can recapitulate the progression of
human cancer development. PanIN, pancreatic
intraepithelial neoplasia; PDAC, pancreatic ductal
adenocarcinoma. (3) Cancer cell heterogeneity can
be controlled by the reprogramming of cancer cells.
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on developmental genes. All together, these results suggest that
hierarchical control of heterogeneous cancer cells could be
bidirectional and that such interconversion could be a promis-
ing target for efficient cancer treatment.
Induction of Dedifferentiation In Vivo Using
Reprogramming Technology
In vivo reprogramming systems have provided a unique plat-
form for studying the role of dedifferentiation in cancer devel-
opment and provided the first in vivo evidence that epigenetic
abnormalities can be a driving force for cancer develop-
ment.(59)
Reprogramming systems in vivo. Stadtfeld et al.(60) generated
mice containing lentivirus-mediated transgenic alleles for
doxycycline (Dox) inducible reprogramming factors. The trans-
genic mice often developed teratomas consisting of differenti-
ated cells of three different germ layers even without Dox
treatment, presumably because of the leaky expression of 4Fs.
Considering that pluripotent stem cells are capable of teratoma
formation, this observation strongly suggested that somatic
cells can be reprogrammed into pluripotent stem cells in vivo.
In a later study, Abad et al.(61) established germline-transmit-
ted mice with lentivirus-mediated Dox-inducible repro-
grammable alleles and found that these mice form teratomas in
response to Dox treatment, again suggesting in vivo repro-
gramming. Notably, these mice formed various types of tumors
(Wilms’ tumor, skin papilloma, urothelial carcinoma and
intestinal polyps) as well as teratomas upon Dox treatment of
various periods.
Ohnishi et al.(59) also established another reprogrammable
mouse model in which the expression of reprogramming fac-
tors can be controlled by Dox and visualized by the fluorescent
protein mCherry.(62) In this system, the induction of repro-
gramming factors for 28 days resulted in multiple formations
of teratomas in various organs. Importantly, in vitro culture of
teratoma tissue led to the derivation of iPSC that could be
used for the generation of adult chimeric mice, demonstrating
that somatic cells are reprogrammable in vivo with this system.
All together, these results showed that the expression of repro-
gramming factors in vivo can alter the cellular identity of adult
somatic cells into the pluripotent state in living mice.
Premature termination of in vivo reprogramming. In repro-
grammable mice, the long-term expression of 4Fs resulted in
the establishment of pluripotent stem cells. Interestingly, the
in vivo phenotype varied with the length of time of the 4F
expression. A short-term induction of 4Fs caused the emer-
gence of dysplastic cancer-like cells exhibiting abnormal pro-
liferation. However, the dysplastic cells disappeared after
withdrawal of 4F expression and reverted to normal-looking
cells. The reversion of the dysplastic phenotype indicates that
continuous expression of 4Fs is required for the maintenance
of the dysplastic cells and further suggests that early dysplastic
cells retain epigenetic memory. However, prolonging the
induction of the reprogramming factors to a period that
remains shorter than that required for teratoma development
caused 4F-independent tumor formation in various organs.
These tumors consisted of dysplastic cells that were distinct
from teratoma cells. Moreover, the dysplastic cells had an
invasion phenotype and in particular cases metastasized into
the lymph node, suggesting that they behave like cancer cells.
Furthermore, the late dysplastic cells exhibited activation of
ESC-Core and ESC-Myc modules, indicating that acquisition
of the transcription network of pluripotent stem cells is associ-
ated with the tumor development.(63)
Interestingly, 4F-independent tumors resemble human pedi-
atric cancers, such as Wilms’ tumor-like tumor in the kidney,
hepatoblasotoma-like tumors in the liver and pancreatoblas-
toma-like tumors in the pancreas. Wilms’ tumor is the most
common pediatric kidney cancer (Fig. 3). Although genetic
mutations, such as WT1 and WTX, have been identified in
Wilms’ tumors, the overall incidence of these mutations is not
high.(64) In contrast, it has been shown that abnormal DNA
methylation patterns at imprinting loci are frequently detect-
able in Wilms’ tumors.(65,66) Of note, the failed reprogram-
Fig. 3. Generation of human pediatric cancer-like
tumors in vivo. An in vivo reprogramming system
was established with Dox-inducible alleles for
reprogramming factors. Premature termination of
in vivo reprogramming in mice causes cancer
development consistent with human pediatric
cancers (Wilm’s tumor-like tumor in the kidney,
hepatoblastoma-like tumor in the liver and
pancreatoblastoma-like tumor in the pancreas).
Fig. 4. Proof of concept for epigenetics-driven cancer development.
In vivo reprogramming results in teratoma formation, whereas prema-
ture termination of the reprogramming leads to pediatric cancer-like
tumors. The tumor cells can be reprogrammed into iPSC that can be
used to generate adult chimeric mice. Note that tumor-derived iPSC in
this model give rise to non-neoplastic cells in the chimeric mice.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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ming-associated tumors lacked detectable genetic mutations in
cancer-related genes, but often exhibited a biallelic expression
of imprinting genes, which was accompanied by abnormal
DNA methylation patterns.(59) These observations suggest that
epigenetic alterations related to the cellular reprogramming
might be involved in the development of a subset of pediatric
cancers.
Proof of concept for epigenetics-driven cancer development
in vivo. Considering that somatic cell reprogramming does not
require particular genetic alterations, but rather a reorganiza-
tion of the epigenome, cancer development through the tran-
sient expression of reprogramming factors raises the possibility
that epigenetic alterations drive carcinogenesis. Notably, upon
the re-induction of reprogramming factors, failed reprogram-
ming-associated cancer cells were reprogrammed into iPSC
with higher efficiency and shorter latency, presumably reflect-
ing the partial reprogramming state of these cells. Of particular
note, kidney cancer-derived iPSC were able to give rise to
non-neoplastic kidney cells after injection into blastocyst.
Given that iPSC derivation and differentiation do not require
genetic mutations, the contribution of cancer-iPSC to non-neo-
plastic kidney has provided the first experimental evidence for
epigenetics-driven cancer development in vivo (Fig. 4).(67,68)
However, considering that endogenous Oct3/4 is deeply
silenced in somatic cells,(69) it is unlikely that expression of
Yamanaka 4 factors is directly involved in the development of
human cancers. It should be noted that somatic cell reprogram-
ming can be achievable with other sets of transcription factors,
which do not include Yamanaka 4 factors.(70,71) In this context,
it would be of great interest to identify environmental factors
that induce such transcription factor expression, which might
eventually cause cellular reprogramming. Further analyses
using human samples are needed to clarify the role of repro-
gramming in human cancer development.
Conclusion
Induced pluripotent stem cell technology has already gained
strong interest for its potential in regenerative medicine and
disease modeling. It is becoming increasingly clear that this
technology can also advance cancer research by uncovering
the role of epigenetic alterations in cancer development and
cancer cell maintenance. Given that the epigenome can be
modified with small chemical compounds, understanding its
role should contribute to effective cancer-treatment strategies.
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